Consider how exchange rules might fit with your strategy
A new wave of exchange guidance is about to hit from the Center for Consumer Information and Insurance Oversight
That's because a new wave of exchange guidance is about to hit from the Center for Consumer Information and Insurance Oversight (CCIIO), the arm of the federal Department of Health and Human Services (HHS) charged with overseeing the implementation of the exchange provisions included in the Patient Protection and Affordable Care Act (PPACA).
CCIIO is charged with developing rules for the establishment and operation of exchanges, including both the Small Business Health Options Program (SHOP) Exchange and the American Health Benefit Exchange (AHBE)-through which lower-income individuals will be able to access tax credits and cost-sharing subsidies toward the cost of their coverage. In addition, the regulations delve into the unique roles and responsibilities that arise should the feds go into a state to establish an exchange.
Also on the docket are rules around the offering of qualified health plans through such exchanges, protocols for how plan information is relayed to consumers, and the process for determining subsidy and/or refundable tax credit eligibility.
SQUARE AWAY THE DETAILS
With all this in mind, here are some of the important questions payers and providers should ask as they review the regulations:
Answering these questions, and the dozens more that will no doubt arise in the course of the regulation-making process.
This column is written for informational purposes only and should not be construed as legal advice.
Cindy Gillespie is managing director for McKenna Long & Aldridge LLP.
Frank Micciche is senior advisor for McKenna Long & Aldridge LLP.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
